- Home
- FKWL vs BMEA Comparison
FKWL vs BMEA Comparison
Compare FKWL & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FKWL
- BMEA
- Stock Information
- Founded
- FKWL 1981
- BMEA 2017
- Country
- FKWL United States
- BMEA United States
- Employees
- FKWL N/A
- BMEA N/A
- Industry
- FKWL Telecommunications Equipment
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- FKWL Utilities
- BMEA Health Care
- Exchange
- FKWL Nasdaq
- BMEA Nasdaq
- Market Cap
- FKWL 67.3M
- BMEA 65.8M
- IPO Year
- FKWL 1996
- BMEA 2021
- Fundamental
- Price
- FKWL $4.70
- BMEA $1.63
- Analyst Decision
- FKWL
- BMEA Strong Buy
- Analyst Count
- FKWL 0
- BMEA 11
- Target Price
- FKWL N/A
- BMEA $27.60
- AVG Volume (30 Days)
- FKWL 23.2K
- BMEA 696.5K
- Earning Date
- FKWL 05-19-2025
- BMEA 05-05-2025
- Dividend Yield
- FKWL N/A
- BMEA N/A
- EPS Growth
- FKWL N/A
- BMEA N/A
- EPS
- FKWL N/A
- BMEA N/A
- Revenue
- FKWL $43,443,375.00
- BMEA N/A
- Revenue This Year
- FKWL N/A
- BMEA N/A
- Revenue Next Year
- FKWL N/A
- BMEA N/A
- P/E Ratio
- FKWL N/A
- BMEA N/A
- Revenue Growth
- FKWL N/A
- BMEA N/A
- 52 Week Low
- FKWL $2.90
- BMEA $1.53
- 52 Week High
- FKWL $7.45
- BMEA $13.43
- Technical
- Relative Strength Index (RSI)
- FKWL 36.89
- BMEA 37.94
- Support Level
- FKWL $4.59
- BMEA $1.61
- Resistance Level
- FKWL $5.00
- BMEA $2.30
- Average True Range (ATR)
- FKWL 0.19
- BMEA 0.21
- MACD
- FKWL 0.02
- BMEA -0.01
- Stochastic Oscillator
- FKWL 31.82
- BMEA 3.11
About FKWL Franklin Wireless Corp.
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.